EAGLE PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q3 2013 to Q4 2022

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Eagle Pharmaceuticals, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q3 2013 to Q4 2022.
  • Eagle Pharmaceuticals, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2022 was $35.1M, a 608% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2022 $35.1M +$30.1M +608% Dec 31, 2022 10-K 2023-03-23
Q4 2021 $4.96M +$1.89M +61.7% Dec 31, 2021 10-K 2023-03-23
Q4 2020 $3.07M +$2.12M +223% Dec 31, 2020 10-K 2022-03-08
Q4 2019 $951K +$951K Dec 31, 2019 10-K 2021-03-05
Q4 2018 $0 $0 Dec 31, 2018 10-K 2020-03-02
Q4 2017 $0 $0 Dec 31, 2017 10-K 2019-02-28
Q4 2016 $0 -$38.5M -100% Dec 31, 2016 10-K 2018-02-26
Q4 2015 $38.5M -$1.66M -4.13% Dec 31, 2015 10-K 2017-03-15
Q4 2014 $40.2M Dec 31, 2014 10-K 2016-02-29
Q3 2014 $38.2M +$5.48M +16.7% Sep 30, 2014 10-K 2016-02-29
Q3 2013 $32.8M Sep 30, 2013 10-K 2016-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.